On Monday, NHS England announced that it has now treated more than 100,000 people for hepatitis C using direct-acting antiviral drugs since 2015, putting the country on course to eliminate the virus years ahead of the World Health Organization’s 2030 target. The press release was thick with the language of institutional triumph: “world-leading,” “pioneering,” a health service “fit for the future.” Professor Sir Stephen Powis, the NHS national medical director, declared that England is “leading the world in the mission to eliminate this disease.”

It is, by any measure, a genuine achievement. Hepatitis C was a slow-motion catastrophe — a blood-borne virus that quietly destroyed livers over decades, disproportionately affecting the poor, the incarcerated, and people who inject drugs. That England is now talking about elimination rather than management is remarkable.

But the press release left something out. The drugs that made this possible — sofosbuvir, ledipasvir, velpatasvir, and their successors — were not invented by the NHS. They were invented by Gilead Sciences, a pharmaceutical company based in Foster City, California, which spent billions developing them and, when the first of them launched in 2013, priced a course of treatment at $84,000 in the United States.

In England, the NHS paid considerably less. How much less? We don’t actually know.

The Price of a Cure Is a State Secret

When the first direct-acting antivirals were approved for NHS use, the list price was around £35,000 per course of treatment. By 2016, NHS England was boasting that its centralized procurement process had driven costs down sharply. A 2020 report from the All-Party Parliamentary Group on Hepatitis C noted that the cost was “widely understood” to be “well below £10,000” per course. A 2026 cost-effectiveness analysis published by the National Institute for Health and Care Research stated that the actual price is “confidential.”

Let that sit for a moment. The single most important number in the entire elimination story — what the British state actually paid to cure 100,000 people of a deadly virus — is a trade secret. The NHS signs confidential agreements with drug manufacturers, and neither party discloses the final per-patient cost. The public is asked to celebrate the result without being allowed to inspect the invoice.

This is not an accident. It is the mechanism. The NHS’s negotiating power comes precisely from its ability to keep prices secret. Gilead and its competitors are willing to offer steep discounts to a monopsony buyer because those discounts won’t be visible to other purchasers — including, crucially, the Centers for Medicare and Medicaid Services in the United States, which is legally required to pay a statutorily defined price based on the average manufacturer price in the commercial market. If the NHS’s real price became the reference point, the whole global pricing architecture would unravel.

One pharmaceutical executive, speaking in a hotel bar at a London health policy conference, put it bluntly: “We give the NHS a price we’d never give the Americans, because the Americans would demand it too, and then the math stops working.”

Who Actually Eliminated the Disease?

The framing of Monday’s announcement is instructive. “NHS set to eliminate hepatitis C ahead of rest of the world,” the headlines read. The active verb belongs to the health service. The drugs themselves are background furniture — “pioneering antiviral drugs” that the NHS “rolled out.”

But the NHS did not discover the NS5A protease inhibitors that make hepatitis C curable. It did not run the clinical trials, navigate the FDA and EMA approvals, or build the manufacturing capacity. It wrote a check. A very large check, negotiated at a very steep discount, but a check nonetheless.

This matters because the elimination narrative is already being absorbed into a broader argument about the superiority of single-payer systems. If the NHS can eliminate hepatitis C, the reasoning goes, imagine what it could do with cancer, with obesity, with dementia — if only it were given more resources and more control.

The counterpoint is uncomfortable: the NHS could eliminate hepatitis C because a treatment existed to be bought. That treatment existed because American pharmaceutical companies, operating in a system that allows them to charge prices the NHS would never countenance, had a profit incentive to develop it. The global pipeline for antiviral drugs is not powered by the purchasing practices of European health ministries. It is powered by the US market, where Sovaldi launched at $1,000 per pill.

The Uncomfortable Symbiosis

None of this is to diminish what the NHS has accomplished. Identifying 100,000 people with a largely asymptomatic disease, getting them into treatment, and curing them is a logistical feat that would strain any health system. The targeted screening programs, the outreach to marginalized populations, the integration with drug treatment services — these are things the NHS genuinely did well.

But the celebration should come with an asterisk. The elimination of hepatitis C in England is not a proof of concept for government-run pharmaceutical innovation. It is a proof of concept for something narrower and more awkward: a monopsony buyer can extract extraordinary value from a global innovation system it did not build and does not fund.

The asterisk will not appear in the press releases. The confidential prices will remain confidential. And the next time a pharmaceutical executive is hauled before a parliamentary committee to explain why a new drug costs what it costs, no one will mention that the NHS’s proudest achievement depends on someone else paying the sticker price.

Sources